Kala Pharmaceuticals (NASDAQ:KALA) will issue its quarterly earnings data before the market opens on Tuesday, August 6th. Analysts expect the company to announce earnings of ($0.74) per share for the quarter.
Kala Pharmaceuticals (NASDAQ:KALA) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.75) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.75). The firm had revenue of $1.39 million during the quarter, compared to the consensus estimate of $0.96 million. On average, analysts expect Kala Pharmaceuticals to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of Kala Pharmaceuticals stock opened at $5.80 on Monday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 9.93 and a current ratio of 10.30. The company has a market capitalization of $196.50 million, a price-to-earnings ratio of -2.34 and a beta of 2.02. Kala Pharmaceuticals has a fifty-two week low of $4.03 and a fifty-two week high of $14.45. The company has a 50-day moving average price of $5.88.
In related news, Director Howard B. Rosen bought 5,000 shares of the firm’s stock in a transaction on Thursday, May 30th. The stock was bought at an average cost of $5.42 per share, for a total transaction of $27,100.00. Following the completion of the purchase, the director now directly owns 8,240 shares in the company, valued at approximately $44,660.80. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 30.77% of the company’s stock.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Further Reading: What is the downside to momentum investing?
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.